



H.C. Wainwright 22nd Annual Global Investment Conference

Anthony Fernando, President & CEO
September 15, 2020

FORWARD LOOKING STATEMENTS



This presentation includes statements relating to the Senhance Surgical System's market development and a general corporate update. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, whether the market development activities related to the Senhance Surgical System will be successful, the pace of adoption of our products by surgeons, the success and market opportunity of our products, the impact on the ongoing pandemic on our business and our customers, our current cash reach, the effect on our business on existing and new regulatory requirements and other economic and competitive factors and whether we will be able to execute upon our corporate objectives. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 16, 2020 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this presentation and speak only as of the origination date of this presentation. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OUR STRATEGIC INTENT

At TransEnterix, we believe in digitizing the interface between the surgeon and patient in laparoscopy to increase control and reduce surgical variability for improved patient outcomes in today's value-based healthcare environment.

COMPANY OVERVIEW

TRANSENERIX (NYSE American:TRXC)

EARLY-COMMERCIAL STAGE COMPANY USHERING IN A NEW ERA OF
MINIMALLY INVASIVE SURGERY



- **Senhance Surgical Robotic System** – the first and only **Digital Laparoscopy** platform
- Significant and differentiated addressable market opportunity
- FDA Cleared, CE Marked and Japan PMDA approved
- Building awareness and ramping up clinical adoption
- Well positioned to bring Augmented Intelligence (AI) and Machine Vision to surgery

COMPANY SNAPSHOT

FIRST NEW ENTRANT IN THE FIELD OF ABDOMINAL SURGICAL
ROBOTICS IN NEARLY 20 YEARS




Active sites in the
U.S., E.U. and Asia

3,400+ Surgeries
Performed, to date


140 global employees
with 30+ customer facing

100+
Surgeon Users



GLOBAL TRENDS IN ROBOTIC SURGERY

SURGICAL ROBOTICS IS A LARGE AND FAST GROWING MARKET
AND LAPAROSCOPIC SURGERY IS A GREENFIELD OPPORTUNITY



VALUE-BASED HEALTHCARE IS FORCING HOSPITALS TO IMPROVE OUTCOMES, EFFICIENCIES, AND TALENT RETENTION

THE PRESSURE AND IMPACT ON SURGEONS ARE INCREASING UNDER
THE CONSTRAINTS OF VALUE-BASED HEALTHCARE



OR
Inefficiencies



Surgical
Variability



Workforce
Challenges



**Laparoscopy is the most
widely performed surgical
technique and carries
limitations that compound
these factors and can
impact clinical outcomes**

Digital laparoscopy seeks to address these limitations

The Senhance Surgical System

SENHANCE SYSTEM ADDRESSES KEY CHALLENGES FACING HOSPITALS AND LAPAROSCOPIC SURGEONS

BUILDING THE BRIDGE FROM LAPAROSCOPY TO ROBOTICS



First robotic system with *Augmented Intelligence (AI) and Machine Vision Capabilities*


First robotic system to *offer the security of haptic feedback*

First robotic system to *offer simultaneous surgeon-controlled visualization*

86 different types of *procedure/technique surgeries performed*

New standard in minimally *invasive surgery with 3mm instruments*

Developed broad instrument *portfolio with 70 instruments in the catalog*



WE ARE UNIQUELY FOCUSED ON DIGITAL LAPAROSCOPY



AN OPPORTUNITY AND NEED TO ADD TO THE WAYS SURGICAL
ROBOTICS CREATES VALUE



Senhance



Da Vinci

	Digital Laparoscopy		Robotic Assisted Surgery	
	Feature	Implication	Feature	Implication
Motion	▪ Lap	▪ Familiarity for laparoscopic surgeons	▪ Open	▪ More enabling for non-laparoscopists
Instruments	▪ Fully reusable	▪ Low cost per procedure	▪ Limited Use (10x max)	▪ High cost per procedure
	▪ 5mm and 3mm	▪ Advances MIS benefit	▪ 8mm	▪ Not improving invasiveness over laparoscopy
Additional Features	▪ Haptic feedback	▪ Restores significant sensory input	▪ Wristed instruments	▪ Enabling but higher cost per procedure
	▪ Eye tracking camera control	▪ Novel surgical vision control		
	▪ Open vision system	▪ Leverage best in class visualization technologies		
	▪ Individual boom arms	▪ Full patient access		
	▪ Articulating instruments	▪ Enabling where needed		

Standard Laparoscopic tools, digital information and decision support tools will be the primary driver of the added value through computer assistance

Competitors are following the Da Vinci model

Our Plan for 2020

2020 – SENHANCE AND DIGITAL LAPAROSCOPY RECOGNIZED AS KEY COMPONENTS FOR ROBOTIC GROWTH



WE ARE FOCUSED ON:

MARKET DEVELOPMENT

- Expand the number of sites using the Senhance System in key geographies
- Double the number of clinical cases
- Increase the number of speakers & advocates cascading our key messages

CLINICAL EVIDENCE

- Publication of evidence supporting Senhance value propositions
 - Cost Effectiveness
 - Clinical Outcomes
 - O.R. Efficiency
 - Ergonomics

PORTFOLIO EXPANSION

- Scene cognition and Augmented Intelligence technology launched in the US
- Full EU launch of 5mm Articulating instruments
- Indication expansion
 - Pediatrics in EU
 - General Surgery in US
 - Bariatric in US


**By End 2020 – Critical mass of advocacy, awareness, and credibility
developed as a foundation to drive future growth**

STRONG, BROAD-BASED CLINICAL PERFORMANCE



SENHANCE DEMONSTRATING STRONG CLINICAL PERFORMANCE
ACROSS THE THREE MAJOR GEOGRAPHIES


GLOBAL CLINICAL CASE VOLUME TREND



Active Sites	6	15	24	30 *
--------------	---	----	----	------

Strong clinical case performance in 2019
Strong momentum in Q1 2020 dampened by COVID

2019/2020 CASE MIX



Adoption across multiple specialty areas,
demonstrating broader applicability and adoption

* TransEnterix Estimates and YTD Actual

THE FIRST MACHINE VISION SYSTEM IN ROBOTIC SURGERY

LEADING THE WAY IN AUGMENTED INTELLIGENCE AND MACHINE VISION IN SURGERY


SENHANCE INTELLIGENT SURGICAL UNIT (ISU)



FDA 510(k) Approved
in March 2020




In Clinical use in
the US




DEFECT IDENTIFICATION AND SIZING


FUTURE FEATURE
ADDITIONS



3D POINT TO POINT MEASUREMENT




CRITICAL STRUCTURE IDENTIFICATION



GENERAL SURGERY OPPORTUNITY IN THE U.S.

GROWTH IN GENERAL SURGERY MUST COME FROM LAPAROSCOPIC MIS PROCEDURES

US Laparoscopic Procedures by Type



- Based on current Senhance FDA 510(k) approval, 1.4M procedures are addressable in the US
- Approximately 800K additional procedure will be addressable with expected FDA 510(k) clearance

Financial Overview & Key Operational Accomplishments

2020 OPERATIONAL HIGHLIGHTS

SIGNIFICANT OPERATIONAL PROGRESS YEAR TO DATE

- Eight Senhance lease agreements signed, 6 clinical programs initiated and completed ~900 cases YTD
- Filed and received FDA clearance for Augmented Intelligence(AI) and machine vision system, Intelligent Surgical Unit (ISU)
- Received CE Mark for Pediatric use of Senhance in Europe
- Made FDA 510(k) submission for General Surgery indication expansion
- Established Asia Pacific Training Center at Saitama Medical University International Medical Center in Japan



FINANCIAL HIGHLIGHTS

PRUDENTLY MANAGING CASH TO FUND EXECUTION



- Pro-forma cash of \$29.9M¹
- Debt-free, except for government promissory note
- Completed restructuring expected to reduce cash burn by 37% in FY2020 compared to FY2019
- Reduced operating expenses by 15% or \$2.4M in Q2 2020 compared to Q1 2020
- Cash sufficient for needs into Q2 2021

1. Includes Q2 2020 cash of \$16.2M and July 6, 2020 public offering net proceeds of \$13.7M

